Baseline characteristics of 259 study participants
| Patient characteristics . | Anagrelide group . | Hydroxyurea group . |
|---|---|---|
| Patients (n) | 122 | 137* |
| Age (median, years, range) | 58.1 (19-90) | 56.4 (22-83) |
| Sex (m/f) | 46/76 | 47/89 |
| Platelet count (median, × 109/L,± quartiles) | 979.5 (837.0/1220.0) | 1044.0 (846.0/1284.0) |
| Hemoglobin (median, g/dL, ± quartiles) | 14.0 (13.0/15.0) | 14.0 (13.0/14.9) |
| WBCs (median, × 109/L, ± quartiles) | 9.4 (8.1/11.2) | 9.5 (8.1/11.8) |
| JAK2 V617F positive (n) | 54 | 53 |
| History of thromboembolic events (n) | 26 | 22 |
| History of bleeding events (n) | 8 | 15 |
| History of ischemic episodes (n) | 26 | 16 |
| Aspirin (n) (100 mg/d, n=41; <75mg/d, n=32) | 35 | 38 |
| Hypertension (n) | 46 | 52 |
| Diabetes mellitus (n) | 4 | 9 |
| Patient characteristics . | Anagrelide group . | Hydroxyurea group . |
|---|---|---|
| Patients (n) | 122 | 137* |
| Age (median, years, range) | 58.1 (19-90) | 56.4 (22-83) |
| Sex (m/f) | 46/76 | 47/89 |
| Platelet count (median, × 109/L,± quartiles) | 979.5 (837.0/1220.0) | 1044.0 (846.0/1284.0) |
| Hemoglobin (median, g/dL, ± quartiles) | 14.0 (13.0/15.0) | 14.0 (13.0/14.9) |
| WBCs (median, × 109/L, ± quartiles) | 9.4 (8.1/11.2) | 9.5 (8.1/11.8) |
| JAK2 V617F positive (n) | 54 | 53 |
| History of thromboembolic events (n) | 26 | 22 |
| History of bleeding events (n) | 8 | 15 |
| History of ischemic episodes (n) | 26 | 16 |
| Aspirin (n) (100 mg/d, n=41; <75mg/d, n=32) | 35 | 38 |
| Hypertension (n) | 46 | 52 |
| Diabetes mellitus (n) | 4 | 9 |
n, patient numbers; WBCs, white blood cells.
One patient was excluded after detection of Ph-chromosome translocation, and 5 patients withdrew after random selection.